Cefpodoxime Proxetil and Potassium Clavulanate Tablets – A potent combination to combat resistant bacterial infections
STADOX CV Tablets – Cefpodoxime 200 mg + Clavulanic Acid 125 mg Tablets brings two potent antibiotics for the effective management of bacterial infections:
Cefpodoxime: A third-generation cephalosporin with broad-spectrum bactericidal activity. It inhibits bacterial cell wall synthesis, effectively treating respiratory, urinary, and skin infections.
Potassium Clavulanate: A beta-lactamase inhibitor is added to protect cefpodoxime from degradation. This combination effectively treats infections caused by beta-lactamase-producing bacteria, offering superior clinical outcomes in managing bacterial infections. Together, this formulation offers rapid resolution of symptoms and minimizes the risk of antimicrobial resistance.
Recommended by specialists:
✅ Pulmonologist: To manage respiratory tract infections like bronchitis and sinusitis.
✅ Urologist: To manage renal infection and urinary tract infection.
✅ Dermatologist: To treat skin and soft tissue infections
✅ ENT Specialists: To manage ENT infections like Otitis media infections, tonsillitis, and pharyngitis.
Key benefits of Cefpodoxime 200 mg + Clavulanic Acid 125 mg Tablets – STADOX CV Tablets
✅ Broad-Spectrum Activity: Combines Cefpodoxime (third-generation cephalosporin) and Potassium Clavulanate (beta-lactamase inhibitor) to effectively target both Gram-positive and Gram-negative bacteria.
✅ Enhanced Efficacy: Synergistic action ensures faster and more comprehensive eradication of bacterial infections, including resistant strains.
✅ Versatile indications: Ideal for treating mixed infections, respiratory tract infections, ENT infections and complicated urinary tract infections.
Indications:
✅ Respiratory tract infections (e.g., pneumonia, bronchitis)
✅ Complicated and uncomplicated urinary tract infections
✅ ENT Infections (Tonsillitis, Pharyngitis)
✅ Skin and soft tissue infections
✅ Mixed bacterial infections